The association between dietary folate intake, two polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase (TYMS), and survival in head and neck squamous cell carcinoma (HNSCC) patients is not clarified.
introduction
Head and neck cancers typically arise from epithelial squamous cells, with >500 000 new cases diagnosed worldwide each year [1] . In Japan, mortalities due to oral and pharyngeal cancers have increased steadily from 1960 to 2000, reaching levels observed in western countries in the 1990s [2] . Approximately 60% of patients present with advanced disease (stages III and IV), for which the prognosis is poor even with multimodal treatment approaches [3] . Although the established prognostic factors are primary tumor site, TNM (tumor-node-metastasis) stage, and comorbidity, including performance status (PS) [4] , the identification of additional prognostic factors may lead to more effective personalized treatment.
Folate is a water-soluble vitamin of the B complex group and plays an important role in one-carbon metabolism, which facilitates de novo deoxynucleoside triphosphate synthesis and provides methyl groups required for intracellular methylation reactions [5] . Based on a number of epidemiologic studies, low dietary folate intake is recognized as an independent risk factor for several types of cancers, including head and neck squamous cell carcinoma (HNSCC) [6] [7] [8] [9] [10] [11] [12] [13] [14] . In addition, an association has been identified between folate-related gene polymorphisms and clinical outcomes for several cancers, such as colorectal, gastric and breast cancer [15] [16] [17] [18] . Two polymorphisms in key enzymes of the one-carbon metabolism pathway in particular, C677T (Single Nucleotide Polymorphism Database (dbSNP)ID, rs1801133) in methylenetetrahydrofolate reductase (MTHFR) [19] [20] [21] and a 6-bp insertion/deletion in the 3#-untranslated region (UTR; dbSNP ID, rs16430) of thymidylate synthase (TYMS) [22] , have been associated with HNSCC risk. From the results of these epidemiologic studies, it is plausible to speculate that folate intake and two polymorphisms affect survival of HNSCC patients and may represent suitable prognostic markers.
To date, however, no studies have evaluated the combined effect of folate intake and genetic polymorphisms on clinical outcomes of HNSCC. Thus, we conducted a cohort study to examine the potential association of these factors among 437 HNSCC patients treated at Aichi Cancer Center (ACC).
patients and methods patients
The patients were selected from the database of the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), which was conducted at ACC located in Nagoya, Japan. The HERPACC framework has been detailed elsewhere [23, 24] . Briefly, 23 408 HERPACC-enrolled first-visit outpatients treated from January 2001 to November 2005 at ACC were asked to provide blood samples in addition to information on lifestyle factors. Of those who participated, 22 727 (97.1%) patients completed a self-administered questionnaire on lifestyle factors, which was checked by a trained interviewer, and 60% provided blood samples. This study was approved by the Institutional Ethics Review Board of ACC, and all participants provided written informed consent.
In the present study, HERPACC-enrolled patients diagnosed as having primary head and neck cancer who met the following criteria were included: (i) no prior history of cancer, (ii) no malignant neoplasms of the salivary glands, nasopharynx, nasal, or paranasal sinuses (these cancers were excluded as they have a distinct etiology), (iii) histologically diagnosed with squamous cell carcinoma, and (iv) PS of zero to two, according to the Eastern Cooperative Oncology Group criteria. Finally, 437 patients were eligible for this study, and 63.4% (277 of 437) of these patients provided blood samples.
evaluation of folate intake and other lifestyle-related exposure
The HERPACC questionnaire included items related to demographic characteristics, individual and family medical histories, height and weight, exercise, smoking and drinking habits, vitamin supplement use, and consumption of selected foods and beverages. We asked information before the period when subjects had presented symptoms or reason to visit Aichi Cancer Center Hospital. All dietary exposures, including folate consumption, were determined by a food-frequency questionnaire (FFQ) [25, 26] , which covered 47 single food items with 8 consumption frequency categories consisting of never or seldom, one to three times/ month, one to two times/week, three to four times/week, five to six times/ week, once/day, twice/day, and three or more times/day. We estimated the average daily intake of nutrients by multiplying the food intake (in grams) or serving size by the nutrient content per 100 g of food as listed in the Standard Tables of Food Composition in Japan. Consumption of nutrients from supplements was not included in total vitamin consumption because the data collected for multivitamins were not quantitative [27] . The FFQ was validated by referring to a 3-day weighted dietary record as a standard, which showed validity and reproducibility to be satisfactory [25] . Energyadjusted intakes of folate were calculated using the residual method, as described previously [28] . The de-attenuated correlation coefficients for energy-adjusted intakes of folate were 0.36 [95% confidence interval (CI) 0.12-0.58] in men and 0.38 (95% CI 0.25-0.62) in women. Moreover, to avoid the potential effect of supplemental folate intake, we included a variable concerning the use of any type of vitamin supplement (yes or no) in the multivariate analysis. In Japan, folate fortification of foods is not obligated by law; therefore, the lack of consideration of fortification was assumed to have minimal effect.
Cumulative smoking exposure was evaluated as pack-years (PY) and was used to divide patients into two groups: PY < 20 and PY ‡ 20. Alcohol consumption was also used to divide patients into two categories: nonheavy drinkers and heavy drinkers. Heavy drinkers were defined as individuals who consumed alcoholic beverages in a daily amount of ‡46 g ethanol (equivalent to two Japanese drinks) for ‡5 days/week; the remaining patients were categorized as non-heavy drinkers [29] .
examination of genetic polymorphisms
The examination of genetic polymorphisms was carried out for the 277 patients who provided blood samples. For each patient, DNA was extracted from the buffy coat fraction of whole blood using a DNA Blood Mini Kit (Qiagen K.K., Tokyo, Japan). Genotyping for the MTHFR C677T polymorphism was carried out using Taqman Single Nucleotide Polymorphism Genotyping Assays (Applied Biosystems Foster City, CA). The 6-bp insertion/deletion (6+/62) in the 3#-UTR of TYMS was determined by PCR using the forward and reverse primers 5#-CAAATCTGAGGGAGCTGAGT-3# and 5#-CAGATAAGTGGCAGTACAGA-3#, respectively, followed by digestion with the restriction enzyme DraI (New England Biolabs, Ipswich, MA). Five percent of the samples were examined in duplicate to evaluate consistency, and 100% agreement was observed.
statistical methods
The primary end point of this study was overall survival (OS), which was defined as the interval between the beginning of treatment and the date of death or last follow-up. Vital and disease status was estimated by checking medical records from the date of the last follow-up visit. For patients lost to follow-up, vital status was confirmed by a census registration conducted annually. Disease-free survival (DFS) was measured as a secondary end point and was defined as the number of days from the beginning of treatment to the date of relapse, which was evaluated and recorded by each physician. The associations between folate intake, genetic polymorphisms, and OS or DFS were evaluated by the Kaplan-Meier product-limit method and uni-and multivariate Cox proportional hazard models. A measure of association in this study was the hazard ratio (HR) along with a 95% CI. Impact of polymorphisms was assessed only in those who provided blood samples. Distribution of patient's characteristics was assessed by the v 2 test or the Fisher's exact test, as appropriate. All statistical analyses were carried out using the software STATA ver. 10 (StataCorp, College Station, TX). All tests were two sided, and P values <0.05 were considered statistically significant.
results patient characteristics and survival Table 1 summarizes the detailed characteristics of the 437 patients evaluated in this study. Median age was 61 years (range 21-79 years), median follow-up time was 4.9 years (range 0.7 months-9.1 years), and males were predominant among the subjects (78%). Approximately 50% of the primary tumor sites were located in the oral cavity, particularly the tongue (66.2%).
The distribution of first-line treatment was 119 for surgery, 38 for radiotherapy (RT), 146 for chemoradiotherapy (CRT), and 134 for induction chemotherapy (IC). In the IC group, CRT or RT was carried out for patients who achieved more than partial response (at least 30% tumor reduction) (n = 100), while all others underwent surgery (n = 34). The IC regimens were as follows: cisplatin + 5-fluorouracil (5-FU; n = 129) and others (n = 5). The CRT regimens were as follows: nedaplatin + 5-FU (n = 61), cisplatin + 5-FU (n = 49), cisplatin alone (n = 21), folate intake and genetic polymorphisms of MTHFR and TYMS among patients Estimated folate intake was divided into three groups: low (£240 lg/day; lowest tertile), medium (>240 and <320 lg/day; middle tertile), and high ( ‡320 lg/day; highest tertile), and the number of patients in these groups was 135, 143, and 144, respectively. The frequencies and allelic variation of the MTHFR C677T and TYMS 3#-UTR (6+/62) polymorphisms are shown in Table 1 . Genotype distributions of the two polymorphisms were in accordance with Hardy-Weinberg equilibrium.
impact of folate intake and genetic polymorphisms on clinical outcomes Table 2 shows the results of the uni-and multivariate analyses of folate and genetic polymorphisms for OS. In the multivariate analysis, HRs for the medium-and high-folate intake groups relative to the low-intake group were 1.17 (95% CI 0.76-1.81) and 0.61 (95% CI 0.38-0.98), respectively. As the threshold folate intake value appeared to occur between 240 and 320 lg/day, we decided to conduct further analyses by dichotomization of the variables, using low/medium (<320 lg/day) versus high ( ‡320 lg/day) folate intake. Patients with high folate intake (n = 144) were significantly associated with improved OS than patients with low and medium folate intake (n = 278; 5-year OS: 79.1% versus 68.2%, respectively; P = 0.020; HR 0.56; 95% CI 0.37-0.84; P = 0.006; Figure 1A ; Table 2 ). In addition, we explored the association between other nutrients and OS using multivariate analysis, but no significant associations were detected (supplemental Table S2 , available at Annals of Oncology online). Patients with the +6/+6 genotype in TYMS 3#-UTR exhibited better OS compared with those with the 26/26 genotype with marginal statistical significance in the multivariate analysis (HR 0.49; 95% CI 0.21-1.13; P = 0.093; P trend = 0.101). The results for DFS were consistent with those for OS ( Figure 1B ; Table 3 ). In contrast, we failed to observe clear associations with the MTHFR polymorphism for either OS or DFS, although the point estimates of the HR for T/T relative to C/C were below unity.
interaction between folate intake and genetic polymorphisms on clinical outcomes Table 4 shows the interaction between folate intake and the two polymorphisms with respect to OS and DFS. We observed no significant interaction between folate intake and either genetic polymorphism on OS or DFS.
interaction between folate intake and other clinical factors
Finally, we also examined the interaction between folate intake and several other clinical prognostic factors of HNSCC (Table 5 ). In nearly all the examined subgroups, high folate intake tended to be associated with improved prognosis of HNSCC patients. Notably, a significant interaction was observed between folate intake and primary tumor site (P for heterogeneity = 0.027). However, the impact of high folate intake on prognosis was less clear in patients whose primary tumor site was located in the oral cavity than those with primary sites in the oropharynx, hypopharynx, or larynx.
discussion
In this study, we found that higher consumption of folate before treatment was significantly associated with improved survival in HNSCC patients. Furthermore, we did not observe an interaction between folate intake and genetic polymorphisms of either MTHFR or TYMS on prognosis, indicating that folate consumption is an independent prognostic factor for HNSCC. To our knowledge, this represents the first study to identify this association and suggests that increasing dietary folate intake before HNSCC treatment may improve survival outcomes. 
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Although the mechanism behind the identified association between folate intake and prognosis of HNSCC is unclear, two mechanisms appear possible based on previous evidence. The first involves alteration of the normal methylation process, and the second may be an imbalance in the steady-state levels of DNA precursors, leading to aberrant DNA synthesis, stability and repair, and chromosomal changes [5, 30] . Regarding DNA methylation, two distinct types have been identified in several cancers, including HNSCC: global and regional hypomethylation and hypermethylation within the CpG islands Figure 1 . Kaplan-Meier survival curves of OS (A) and DFS (B). Patients with high folate intake (n = 144) had significantly higher OS and DFS than patients with low or medium folate intake (n = 278) (5-year OS: 79.1% versus 68.2%, respectively, P = 0.020; HR 0.56; 95% CI 0.37-0.84; P = 0.006 and 5-year DFS: 62.5% versus 52.7%, respectively, P = 0.041; HR 0.67; 95% CI 0.48-0.93; P = 0.015). OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval. original articles Annals of Oncology of specific gene promoters [31, 32] . Global and regional DNA hypomethylation are known to induce proto-oncogene activation and chromosomal instability, while regional DNA hypermethylation is associated with transcriptional silencing of tumor suppressor genes [33] . Therefore, DNA methylation modifications, which are possibly mediated by dietary folate intake levels, may affect the prognosis of HNSCC [34] . The second possible mechanism by which folate intake influences HNSCC prognosis involves thymidine synthesis, which may be important for maintaining DNA stability [5] . Moreover, folate is known to potentiate the antitumor effects of fluorouracil (FU), a major cytotoxic agent for HNSCC therapy [35] . Supporting this speculation, folinic acid, which increases the 5,10-methylene tetrahydrofolate (THF) levels in cancer cells, results in tighter ternary complexes of thymidylate synthase (TS), 5,10-methylene THF, and 5-fluoro-deoxyuridine monophosphate [35] and increases the antitumor effects of FU in HNSCC [36] . In the present study, we observed an association between higher folate intake and improved clinical outcomes in the subpopulation treated with CRT and IC regimens including FU. Despite these findings, further study is needed to clarify the potential mechanism behind folate intake and HNSCC prognosis.
Regarding genetic polymorphisms in MTHFR and TYMS, although we did not observe significant associations with prognosis, TYMS showed suggestive association. To date, only a single study has directly evaluated treatment outcomes of HNSCC based on TS activity [37] , but no statistically significant relationship was observed between TS activity and response to FU-based IC. In addition, it was shown that the distribution of reduced folates in tumors was significantly higher for complete responders in comparison with patients with less than partial responses. However, the methodology differed from our study as we simultaneously evaluated treatment efficacy (OS and DFS), folate intake levels, and genetic polymorphisms in this study. As the number of studies related to the influence of folate intake and folate-related genes in HNSCC patients is limited, additional studies are needed to confirm our present findings.
Our study had several methodological strengths. First, as the exposure of interest, folate intake before treatment, and polymorphisms of MTHFR and TYMS remained unchanged for individual HNSCC patients, the chronological relation between exposure and outcome could be clearly evaluated. Moreover, because clinicians involved in the care of study patients were not aware of exposure status, information bias was less likely to be introduced. Secondly, potential confounders, such as clinical factors and PS, were considered in the analyses; therefore, the observed associations were theoretically independent of confounders, although we cannot completely rule out the effect of residual confounding by unevaluated factors, for example, human papillomavirus status. Finally, given that our allele frequencies were comparable with those previously reported in public databases, bias in the distribution of selected polymorphisms was negligible.
Several methodological limitations in this study also warrant mention. First, the FFQ was relatively short, and the validity and reliability of folate intake were only modest. Secondly, it is possible that high folate intake represents a surrogate marker for other unknown behaviors that influenced treatment outcomes. However, we attempted to include other possible cofounders in the analyses to minimize this bias. Thirdly, we did not carry out validations between estimated nutrients and biomarkers such as serum folate concentration. Finally, we did not estimate behavioral changes after the initial diagnosis of HNSCC.
In conclusion, this represents the first report to concurrently evaluate the effects of dietary folate intake before treatment and genetic polymorphisms of folate-related genes on clinical outcomes of HNSCC patients. Our results indicate that increasing dietary folate intake before treatment may play an important role in affecting the outcomes of HNSCC patients. To confirm these findings, further prospective investigation is warranted. 
